Form 4: Immunovant Director Atul Pande Sells 6,000 Shares

Director Atul Pande executed a pre-planned sale of 6,000 shares of Immunovant, Inc. at $32.00 per share following an option exercise.

Summary

• Atul Pande exercised options to acquire 6,000 shares of common stock at an exercise price of $8.43 per share.
• The acquired 6,000 shares were subsequently sold at a price of $32.00 per share.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on December 26, 2025.
• Following these transactions, Pande directly owns 116,731 shares and indirectly owns 20,000 shares through a trust.
• The reporting person indicated that they are no longer subject to Section 16 reporting requirements.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and the director retains a significant equity stake despite the change in reporting status.

Positives

• The director realized a significant gain, selling shares at nearly four times the exercise price.
• The director maintains a substantial ownership position of over 136,000 total shares.
• The sale was conducted via a Rule 10b5-1 plan, providing transparency and reducing concerns about opportunistic timing.

Negatives

• Insider selling, even when planned, can occasionally be viewed as a lack of conviction by some market participants.
• The reporting person is transitioning out of Section 16 reporting status.

Risks

• No specific business or operational risks are disclosed in this transaction report.

Future Outlook

No forward-looking guidance or strategic updates are provided.

Industry Context

StockSavvy.ai notes that Immunovant is a key player in the FcRn inhibitor space, and while insider sales are common, the transition of a director out of Section 16 reporting status is a notable governance update.

Comparison to Industry Standards

• The use of 10b5-1 plans is standard for biotech firms like Argenx to manage insider liquidity.
• The retention of over 130,000 shares post-sale is a positive sign of alignment compared to peers where insiders often liquidate larger percentages of their holdings.

Management Changes

Related Party Transactions

• Atul Pande, a director, engaged in the exercise and sale of equity securities.

Stakeholder Impact

• Shareholders may note the departure of a director from Section 16 reporting status, though the sale was pre-planned.

Next Steps

• Monitor for any formal announcement regarding board composition changes.
• Track upcoming clinical milestones for the company's lead assets.

Key Dates

Recommendation

The transaction is a routine exercise and sale under a 10b5-1 plan. While the reporting person is no longer subject to Section 16, the pre-planned nature of the exit and the remaining holdings suggest no immediate cause for concern.

Keywords

Immunovant, IMVT, Insider Selling, Form 4, Atul Pande, Stock Options, Rule 10b5-1, Biotechnology